-
Electronic (PDF)
-
Site License
-
Enterprisewide
RegeneRx Biopharmaceuticals, Inc. - Product Pipeline Review - Q4 2010
GlobalData, November 2010, Pages: 42
RegeneRx Biopharmaceuticals, Inc. – Product Pipeline Review – Q4 2010
Summary
Global Market Direct’s pharmaceuticals report, “RegeneRx Biopharmaceuticals, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- RegeneRx Biopharmaceuticals, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of RegeneRx Biopharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of RegeneRx Biopharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the RegeneRx Biopharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate RegeneRx Biopharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of RegeneRx Biopharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the RegeneRx Biopharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with RegeneRx Biopharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of RegeneRx Biopharmaceuticals, Inc. and identify potential opportunities in those areas.
List of Tables
List of Figures
RegeneRx Biopharmaceuticals, Inc. Snapshot
RegeneRx Biopharmaceuticals, Inc. Overview
Key Information
Key Facts
RegeneRx Biopharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
RegeneRx Biopharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
RegeneRx Biopharmaceuticals, Inc. – Pipeline Products Glance
RegeneRx Biopharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
RegeneRx Biopharmaceuticals, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
RegeneRx Biopharmaceuticals, Inc. – Drug Profiles
RGN-137
Product Description
Mechanism of Action
R&D Progress
RGN-259
Product Description
Mechanism of Action
R&D Progress
RGN-259
Product Description
Mechanism of Action
R&D Progress
RGN-352
Product Description
Mechanism of Action
R&D Progress
RGN-352
Product Description
Mechanism of Action
R&D Progress
RGN-457
Product Description
Mechanism of Action
R&D Progress
TB4 peptide research programme
Product Description
Mechanism of Action
R&D Progress
RegeneRx Biopharmaceuticals, Inc. – Pipeline Analysis
RegeneRx Biopharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
RegeneRx Biopharmaceuticals, Inc. Pipeline Products By Target
RegeneRx Biopharmaceuticals, Inc. – Pipeline Products by Route of Administration
RegeneRx Biopharmaceuticals, Inc. – Recent Pipeline Updates
RegeneRx Biopharmaceuticals, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
RGN-259
RegeneRx Biopharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Nov 17, 2010: RegeneRx Receives Australian Patent Using TB4 For Treatment Of Gastrointestinal Disorders
Nov 02, 2010: RegeneRx Announces Positive Results Of Preclinical Dry Eye Study
Aug 02, 2010: RegeneRx Reports British Researchers' Preclinical Findings Showing That TB4 Is Essential To Heart Development
Jul 19, 2010: RegeneRx' TB4 Shows Improvement In Neurological Function After Stroke
May 14, 2010: RegeneRx Announces Publication Of First Human Data On RGN-259 In Archives Of Ophthalmology
May 13, 2010: RegeneRx Awarded $3 Million Grant From National Institutes Of Health For Development Of Heart Attack Drug
Feb 26, 2010: Regenerx Announces Publication Of Thymosin beta 4 Data In FASEB Journal
Feb 05, 2010: Regenerx Announces Increase In Skeletal Muscle By TB4 For The Prevention Of Duchenne Muscular Dystrophy
Dec 09, 2009: RegeneRx Announces Phase I Trial Of RGN-352 For Cardiovascular Tissue Repair
May 04, 2009: RegeneRx Receives Australian Patent For Treating Eye Disorders With Tß4
Financial Deals Landscape
RegeneRx Biopharmaceuticals, Inc., Deals Summary, 2004 to 2010
RegeneRx Biopharmaceuticals, Inc. Detailed Deal Summary
Equity Offering
RegeneRx Biopharmaceuticals Completes Private Placement Of $1 Million
RegeneRx Biopharmaceuticals Completes Registered Direct Offering Of $3.7 Million
RegeneRx Completes Private Placement Of $9.55 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW6
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
